Hepatitis Forums

Fatty Liver Disease Main Forums => Nonalcoholic Steatohepatitis (NASH) => Topic started by: Hep Editors on February 05, 2020, 10:53:05 am

Title: MSDC-0602K Shows Promise for People With NASH
Post by: Hep Editors on February 05, 2020, 10:53:05 am

MSDC-0602K, an experimental insulin sensitizer, led to improved glucose metabolism and lower liver enzyme levels in people with non-alcoholic steatohepatitis (NASH), though it did not significantly improve liver biopsy findings, according to a report presented at The Liver Meeting, the annual meeting of the American Association for the Study of Liver Diseases, this month in Boston.

NASH and its less severe form, non-alcoholic fatty liver disease (NAFLD), are responsible for a growing proportion of advanced liver disease. The buildup of fat in the liver triggers inflammation, which over time can lead to fibrosis (buildup of scar tissue), cirrhosis (severe scarring) and liver cancer.

Read more...
https://www.hepmag.com/article/msdc0602k-shows-promise-people-nash